文献速递流行病学与生物统计临床试验与 GCP

有前景的亚组发现的证据级别:趋势与多亚组的情形

Level of evidence for promising subgroup findings: The case of trends and multiple subgroups.
PubMed 文献 · Stat Med · 2019-03-13

该文关注确证性临床试验总体治疗效应未达统计学显著时亚组分析的方法学问题。基于模拟研究,评估有序亚组(如生物标志物,可考察趋势)与同时考察多个协变量即多亚组两种情形下亚组发现的可信度,并为评价此类亚组发现的证据强度提供实用建议。

要点

  • 总体效应未显著时,亚组分析可用于探索特定亚组是否仍可能获益。
  • 研究聚焦有序亚组的趋势分析与多协变量同时分析两种情形。
  • 基于模拟研究评估总体不显著试验中亚组发现的可信度并提出实用建议。

核心结论

  • 论文基于模拟研究评估总体不显著试验中亚组发现的可信度,并为评价此类情形下亚组发现的证据强度提供实用建议。

研究设计与样本

  • 基于模拟研究,考察二分类结局试验中非确证性策略下的两种情形:协变量为有序亚组(如生物标志物)时可研究趋势;同时考察多个协变量即多个亚组。

主要发现

  • 研究针对二分类结局,在总体治疗效应未达统计学显著的试验中评估亚组发现的可信度,涵盖有序亚组的趋势分析与多亚组同时分析两种情形。

临床怎么用

  • 作者基于模拟研究结果为评价总体不显著试验中亚组发现的证据强度提供实用建议。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Subgroup analyses are an essential part of fully understanding the complete results from confirmatory clinical trials. However, they come with substantial methodological challenges. In case no statistically significant overall treatment effect is found in a clinical trial, this does not necessarily indicate that no patients will benefit from treatment. Subgroup analyses could be conducted to investigate whether a treatment might still be beneficial for particular subgroups of patients. Assessment of the level of evidence associated with such subgroup findings is primordial as it may form the basis for performing a new clinical trial or even drawing the conclusion that a specific patient group could benefit from a new therapy. Previous research addressed the overall type I error and the power associated with a single subgroup finding for continuous outcomes and suitable replication strategies. The current study aims at investigating two scenarios as part of a nonconfirmatory strategy in a trial with dichotomous outcomes: (a) when a covariate of interest is represented by ordered subgroups, eg, in case of biomarkers, and thus, a trend can be studied that may reflect an underlying mechanism, and (b) when multiple covariates, and thus multiple subgroups, are investigated at the same time. Based on simulation studies, this paper assesses the credibility of subgroup findings in overall nonsignificant trials and provides practical recommendations for evaluating the strength of evidence of subgroup findings in these settings.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Tanniou J, Smid SC, van der Tweel I, et al. Level of evidence for promising subgroup findings: The case of trends and multiple subgroups. Stat Med. 2019. PMID: 30868624. doi:10.1002/sim.8133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。